PROVENGE Targets and Attacks Prostate Cancer Cells
PROVENGE is the first and only FDA-approved personalized immunotherapy for advanced prostate cancer.
PROVENGE is made by culturing a patient's own immune cells with a recombinant antigen* that is prostate specific. When infused into the patient, PROVENGE activates T cells to TARGET and ATTACK prostate cancer cells.
*The recombinant antigen is PAP-GM-CSF. It consists of prostatic acid phosphatase (PAP), an antigen expressed in more than 95% of prostate cancers, and granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-cell activator.